Fate Therapeutics


ATLANTA, GA – – (Newsfile Corp. – January 23, 2023) – – Holzer & Holzer, LLC informs investors that a class action lawsuit has been filed against Fate Therapeutics, Inc. (“Fate Therapeutics” or the “Company”) (NASDAQ: FATE).  The lawsuit alleges Fate Therapeutics made materially false and/or misleading statements and/or failed to disclose material adverse facts, including: (i) the Janssen Collaboration Agreement was less sustainable than Fate had represented to investors; (ii) accordingly, certain clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (iii) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement on Fate’s long-term clinical and commercial profitability.

If you bought shares of Fate Therapeutics between April 2, 2020 and January 5, 2023 and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at https://holzerlaw.com/case/fate-therapeutics/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is March 22, 2023.

Registration Deadline

Lead Plaintiff Deadline Has Passed

March 22, 2023

Submit Your Information

MM slash DD slash YYYY
Shares Purchased(Required)
Number of Shares Acquired
Acquisition Price Per Share
MM slash DD slash YYYY
Shares Sold
Number of Shares Sold
Selling Price Per Share
By clicking on the button below, I am requesting Holzer & Holzer, LLC send me documents necessary to retain the firm.